2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.
Primary completion date changed from estimate of Sep 30, 2024 to May 9, 2026
Also in this update: Enrollment closed, study ongoing
Zhejiang Cancer HospitalPhase 2 NCT06055816 Registry history of NCT06055816 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 25, 2025 to Mar 13, 2025
Zhejiang Cancer HospitalNot applicable NCT06704698 Registry history of NCT06704698 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-02 | NCT07855640 Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal… | Recruiting | |
| 2026-10-02 | NCT07855757 Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ… | Active, Not Recruiting | |
| 2026-09-30 | NCT07849712 An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment… | Not Yet Recruiting |
| Early Phase 1 | 2 | |
| Phase 1 | 1 | |
| Phase 1/2 | 6 | |
| Phase 2 | 37 | |
| Phase 2/3 | 1 | |
| Phase 3 | 6 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT05148767 | UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer | Rectal Cancer Stage III | Recruiting | 2021-12-08 |
| Phase 3 | ||||
| NCT07235930 | Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG… | Non-Resectable Pancreas Carcinoma | Recruiting | 2025-11-19 |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer… | Colon Cancer | Recruiting | 2024-09-24 |
| NCT06214195 | The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related… | Cardiotoxicity Induced by Drug Therapy for Breast Cancer | Recruiting | 2024-01-19 |
| NCT04974346 | Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer | Cervical Cancer | Recruiting | 2022-01-25 |
| NCT07691515 | Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus… | Intrahepatic Cholangiocarcinoma (Icc) | Not Yet Recruiting | 2026-07-14 |
| NCT07074353 | Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer | Locally Advanced Rectal Cancer | Not Yet Recruiting | 2025-07-25 |
| Phase 2/3 | ||||
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | Liver Tumor; Surgery | Not Yet Recruiting | 2025-04-04 |
| Phase 2 | ||||
| NCT07441720 | Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced… | Thrombocytopenia | Recruiting | 2026-10-13 |
| NCT07602907 | Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A… | Advanced Breast Cancer | Recruiting | 2026-08-11 |
| NCT07162714 | SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer | Rectal Cancer | Recruiting | 2026-08-07 |
| NCT07538635 | CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma… | High-risk R/R LBCL | Recruiting | 2026-05-13 |
| NCT07554898 | Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for… | MALT Lymphoma | Recruiting | 2026-05-11 |
| NCT07416890 | Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1… | Pirtobrutinib | Recruiting | 2026-02-18 |
| NCT07330544 | A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant… | Breast Cancer | Recruiting | 2026-01-09 |
| NCT07325630 | Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric… | IBI363 + Chemotherapy | Recruiting | 2026-01-08 |
| NCT07284836 | Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic… | Hepatic Artery Infusion | Recruiting | 2025-12-16 |
| NCT07285941 | Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian… | Ovarian Cancer | Recruiting | 2025-12-16 |
| NCT06509568 | Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable… | Esophageal Squamous Cell Carcinoma | Recruiting | 2025-08-29 |
| NCT07014410 | Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and… | Breast Cancer | Recruiting | 2025-06-11 |
| NCT05557578 | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors… | Intrahepatic Cholangiocarcinoma | Recruiting | 2025-02-11 |
| NCT05920863 | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the… | Hepatocellular Carcinoma | Recruiting | 2025-02-11 |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced… | Triple-negative Breast Cancer | Recruiting | 2024-11-26 |
| NCT06292689 | A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or… | Vulvar and Vaginal Cancer | Recruiting | 2024-11-21 |
| NCT06674096 | RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL | Double-expressor Lymphoma | Recruiting | 2024-11-18 |
Breast Cancer (14) · Head & Neck Cancer (8) · Gastric Cancer (6) · Cervical Cancer (5) · Colorectal Cancer (5) · Esophageal Cancer (5) · Non-Hodgkin Lymphoma (4) · Ovarian Cancer (4) · Pancreatic Cancer (4) · HER2-Positive Cancer (3)